Update in Tuberculosis/Pulmonary Infections 2015

Affiliations

¹ 1 Division of Global Health Equity, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; and.
² 2 Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts.

Review

Serena P Koenig et al. Am J Respir Crit Care Med. 2016.

. 2016 Jul 15;194(2):142-6.

doi: 10.1164/rccm.201601-0129UP.

¹ 1 Division of Global Health Equity, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; and.
² 2 Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts.

No abstract available

References

1. World Health OrganizationGlobal tuberculosis report 2015. 2015[accessed 2015 Dec 20]. Available from: http://www.who.int/tb/publications/global_report/en/
1. Mehra S, Foreman TW, Didier PJ, Ahsan MH, Hudock TA, Kissee R, Golden NA, Gautam US, Johnson AM, Alvarez X, et al. The DosR regulon modulates adaptive immunity and is essential for Mycobacterium tuberculosis persistence. Am J Respir Crit Care Med. 2015;191:1185–1196. - PMC - PubMed
1. Voskuil MI, Schlesinger LS. Toward resolving the paradox of the critical role of the DosR regulon in Mycobacterium tuberculosis persistence and active disease. Am J Respir Crit Care Med. 2015;191:1103–1105. - PubMed
1. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, Falzon D, Floyd K, Gargioni G, Getahun H, et al. WHO’s Global TB Programme. WHO’s new end TB strategy. Lancet. 2015;385:1799–1801. - PubMed
1. Zellweger JP, Sotgiu G, Block M, Dore S, Altet N, Blunschi R, Bogyi M, Bothamley G, Bothe C, Codecasa L, et al. TBNET. Risk assessment of tuberculosis in contacts by IFN-γ release assays: a Tuberculosis Network European Trials Group study. Am J Respir Crit Care Med. 2015;191:1176–1184. - PubMed